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I. Abstract: 
Modern HIV-1 therapies have led to significant improvements in both quality of life 
and helping to achieve suppression levels capable of preventing further transmission. 
These antiretroviral drugs are given in combination to suppress viral replication and 
overcome the high genetic diversity typical in an HIV-1 infection, diversity that would 
result in drug resistance mutations if the drugs were given singly or not at all. Therapy 
failure is, therefore, highly complex and true resistance must overcome the 
combinatorial genetic barriers of multiple drugs. The purpose of this study was to 
analyze two cohorts of participants: the first who had previously taken combinatorial 
therapy to inhibit the viral enzyme reverse transcriptase (i.e. the viral RNA-dependent 
DNA polymerase) and the second who were beginning therapy for the first time. 
These participants were given the same treatment and followed for the effects that 
first and second exposure to antiretroviral therapy had on the development of drug 
resistance, and whether pre-existing drug resistance mutations (DRMs) were predictors 
of therapy failure during first or second exposure. Therapy failure was characterized by 
initial viral suppression followed by an increase in blood viral loads, or a distinct 
increase in viral load following therapy initiation. Blood plasma samples were collected 
from a cohort of pregnant women in Malawi and viral RNA, purified from the plasma, 
was sequenced using Primer ID and next gen sequencing protocols. This approach 
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allowed for the accurate detection of resistance mutations as minor variants in the 
population. Overall, the results indicate that drug resistance mutations were impactful 
when there were multiple mutations present, or when controlling for participants 
which presented as having poor adherence. Drug abundance, however, was not a 
significant contributor to therapy failure and even with low initial mutation frequency, 
participants with drug resistance ultimately failed therapy. This indicates that drug 
resistance and poor adherence are co-contributors to majority of these therapy failure 
outcomes. This research is important to identify the impact low level drug resistance 
plays in treatment failure for HIV-1, and the potential for drug resistant strains to 
attenuate and spread between people. Additionally, it indicates the importance of 
adherence as imperative for successful viral suppression. 
  
II. Introduction 
Human immunodeficiency virus type 1 (HIV-1) emerged in the 1980s across the 
world, and over the course of 40 years has expanded to every country. HIV-1 is a 
retrovirus that destroys the immune system by binding to and infecting CD4+ T-cells. 
The virus proliferates in these cells within the body while simultaneously attenuating 
the host adaptive immune defenses. Infection progression can be measured both by 
viral load in the blood plasma and by the decreasing CD4+ T-cell count (1). Once an 
individual’s CD4+ T-cell count falls below a threshold of 200 CD4+ T-cells per cubic 
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millimeter of blood or they experience opportunistic infections or certain cancers, that 
individual is said to have an acquired immune deficiency syndrome or AIDS. HIV-1 
treatment uses combinations of antiretroviral inhibitors, called ART or antiretroviral 
therapy, which target multiple points in the HIV-1 life cycle to inhibit viral replication 
(2,3). In 2019, 38.0 million people globally were living with HIV-1, of which 26 million 
were accessing antiretroviral therapy. Over the course of the pandemic, 32.7 million 
people have died of AIDS-related illnesses, and 1.7 million new infections occurred in 
2019 (4). While the rate of successful viral suppression is fairly high for those on 
therapy, the impact of drug resistance can be significant. Fluctuations in viral load as a 
result of poor adherence or other contributors affecting drug exposure can result in 
the selection for drug resistance mutations and virus rebound, i.e. therapy failure; the 
potential transmission of these drug resistance strains is a significant risk and has the 
potential to increase therapy failure rates among those initiating therapy for the first 
time thus limiting the utility of therapy (5). 
Previous studies have provided mixed conclusions about the impact of drug 
resistance on treatment failure, particularly for low abundance resistance mutations 
detected at therapy initiation. Some reports have claimed that the presence of low 
abundance resistance mutations has a significant impact on treatment failure, while 
others have countered that low abundance resistance mutations are not a predictor of 
therapy failure (5-9). These studies have been performed primarily examining drugs 
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that target the viral enzyme reverse transcriptase (RT), and the detection of resistance 
mutations in this genomic region has been central to the polarized debate. Studies on 
the viral integrase and protease coding regions, which are alternate therapy targets, 
have largely found that drug resistance mutations (DRMs) have minimal impact (5). Li 
et al. generated a meta-analysis of 10 previously published studies and corresponding 
data in an attempt to determine the risk associated with low-frequency HIV-1 drug 
resistance mutations. Their ultimate conclusion was that these mutations conferred a 
greater than 2-fold risk of therapy failure for people who are treatment naïve (5).  
The limitations of these studies are the small sample sizes and inadequate 
accuracy for detecting minor variants in the studies used in the pooled analysis. Also, 
these studies used varying definitions of therapy failure outcomes, differing protocols 
for sequence variant detection, disparate cohorts, and overall failed to acknowledge 
the likelihood of adherence as confounding to treatment failure. Particularly, the 
reliance on self-reporting as adequate assessment of adherence is likely problematic. 
Ultimately, there is a gap in the field for a long term study, with a large cohort, that 
can generate significant amounts of data about drug resistance as minor variants in 
people initiating therapy, and that is what my work attempts to achieve. The studying 
of a cohort of participants upon second exposure to therapy is also a novel analysis 
group. This research intends to combine a large group of samples from women 
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starting therapy to provide clearer conclusions regarding the role of minor variants 
with drug resistance and therapy failure. 
This study focuses on samples from two cohorts of pregnant women in 
Lilongwe, Malawi receiving treatment from the UNC-Project Malawi as part of an NIH-
sponsored study with Dr. Mina Hosseinipour as the lead study investigator. In sub-
Saharan Africa, young women between the ages of 15 and 24 are twice as likely to be 
living with HIV-1 compared to men. In this region, women account for 59% of all new 
infections while globally they represent 48% (4). Women are at risk of transmitting the 
infection to their children during pregnancy, birth, or while breast feeding, 
contributing to the 1.8 million people under the age of 14 living with HIV-1 today (4). 
The country of Malawi has a particularly large HIV-1 burden with 1.1 million total cases, 
with an 8.9% prevalence in adults between the ages of 15 and 49. Within this range 
the prevalence is higher for women, 10.8% compared to 7.0% in men (10). While these 
levels are very high, Malawi has impressively approached the UN’s 90-90-90 goals. In 
Malawi 90% of people are aware of their HIV-1 status, of those 88% are on 
antiretroviral therapy (ART), and 91% of people on ART are virally suppressed (10). 
Understanding treatment failure is an important step in maintaining that progress. 
The virulence of HIV-1 stems from its high mutation rate, large population size 
within a person, and short replication cycle. These traits allow infections to overcome 
single antiretroviral inhibitors necessitating the use of a combinatorial therapy. Given a 
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longer time to replicate without suppression, HIV-1 can generate significant diversity 
to overcome moderate selective pressure with escape mutations (11). With poor drug 
adherence, partial suppression can allow for the selection of drug resistant strains (12). 
Participants in the current study were on a combination treatment of three reverse 
transcriptase inhibitors (RTIs) that can be further divided into two categories: 
nucleoside/nucleotide RTIs (NRTIs) and non-nucleoside RTIs (NNRTIs) (2,3). Reverse 
transcriptase is involved in the conversion of viral RNA to DNA and is a primary target 
for inhibiting HIV-1 replication (2,3). The three inhibitors given to participants were the 
NRTIs tenofovir and lamivudine, and the NNRTI efavirenz. The drug resistance 
mutations assessed were the known resistance mutations to these drugs as 
documented in the Stanford HIV-1 drug resistance database (13,14). 
NextGen deep sequencing (NGS) was used in this project. This approach was 
coupled with multiplexed Primer ID (MPID). MPID gives the cDNA product of each 
viral RNA template its own unique degenerate nucleotide block as well as a barcode 
to link individual samples within a pool with their original participant. All sequences 
with the same nucleotide block are pooled to make a highly accurate consensus 
sequence for that template. The total number of template consensus sequences 
(TCSs) generated for each amplified region for each participant gives the sampling 
depth of the viral population. This number was used to define the sampling limit of 
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detection according to the Poisson distribution for the abundance of different 
mutations identified (15-17). 
The two cohorts analyzed here are distinguished based on their therapy history. 
Participants in “cohort A” entered the study having reported no previous therapy 
exposure. In contrast, those in “cohort C” had previously received therapy and, for 
unreported reasons, stopped taking treatment. This previous exposure to therapy was 
anticipated to be associated with the potential for establishing drug resistance 
mutations, while the therapy naive cohort had the potential to carry viruses with 
transmitted drug resistance. After therapy initiation the women were followed to 
assess therapy success (suppression of viral replication) or therapy failure (persistence 
of rebound of viral load). This project analyzes preliminary data generated using entry 
and rebound samples from these two cohorts to determine if pre-existing minor or 
major drug resistance mutations were associated with therapy failure, and on potential 
differences in the type or frequency of drug resistance between these two cohorts. 
 
III. Methods 
Human plasma samples. Plasma samples were collected with informed consent from 
cohorts of pregnant women in Lilongwe, Malawi. These samples were stored at -80ºC 
until beginning the sequencing protocol. 
Primers. The primer sequences targeting the RT amplicons are presented in Table 1. 









PCR1 Forward F2620_AD 
GCCTCCCTCGCGCCATCAGAGATGTGTATAAGAGACAGN 
NNNGGCCATTGACAGAAGAAAAAATAAAAGC 
PCR1 Reverse adaptor_2a GTGACTGGAGTTCAGACGTGTGCTCNA 
PCR2 Primer P1 
AATGATACGGCGACCACCGAGATCTACACGCCTCCCTCG 
CGCCATCAGAGATGTGNA 
PCR2 Primer Index 
CAAGCAGAAGACGGCATACGAGATNNNNNNGTGACTGG 
AGTTCAGACGTGTGCTCNA 
Table 1. Primer sequences used in each step of the protocol. 
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Methods Figure 1. Workflow of the Protocol 
 
RNA extraction and cDNA synthesis. All plasma samples (500 µL) were centrifuged at 
22,000 rpm (Eppendorf, Hamburg, Germany) for 2 hours at 4ºC to pellet viral particles, 
and most of the supernatant (360 µL) was removed and stored. The remaining plasma 
was used to resuspend the viral particles. The viral RNA was extracted from the 
resuspended virus pellet using the QIAmp viral RNA minikit (Qiagen, Valencia, CA). 
Part of the resulting 50 µL product of purified viral RNA was used for cDNA synthesis 
(23 µL) and the rest was stored. The cDNA primer was synthesized by Integrated DNA 
Technologies (Coralville, IA) specifically targeting the reverse transcriptase (RT) region 
of interest in the HIV-1 genome. 
 The 40 µL cDNA reaction mixture was prepared with 10 units of Superscript III 
reverse transcriptase (Life Technologies, Grand Island, NY), 2 units of RNaseOUT (Life 
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Technologies), 5 mM dithiothreitol (DTT), 1x of First Strand buffer (Life Technologies), 
0.5 mM deoxynucleoside triphosphates (dNTPs) and 0.25 µM of cDNA primer. First, 
the dNTPs, primer and template were mixed and heated at 65ºC for 5 min then 
cooled to 2ºC and held there for 2 minutes. Following cooling the rest of the 
components were added and the reaction was incubated at 50ºC for 1 hr, was raised 
to 55ºC for 1 hr and finished at 70ºC for 15 min to inactivate the SSIII reverse 
transcriptase. Finally, 0.5 µL of RNase H was added to each tube and they were 
incubated for 20 minutes at 37ºC to remove any remaining RNA.  
cDNA purification. Agencourt RNA Clean XP Beads (Beckman Coulter, Brea, Ca) were 
used to purify the cDNA products. The beads were added in a 0.6 beads to cDNA 
volume ratio and washed four times with 70% ethanol before elution with 23.5 µL of 
distilled water.  
PCR amplification. Following purification, all of the cDNA product was used for 
amplification. Each reaction was prepared according to the KAPA 2G Robust PCR kit 
(Kapa Biosystems, Woburn, MA) with the forward and adaptor_2A primers shown in 
Table 1, ordered from Integrated DNA Technologies (Coralville, IA). The cycling 
conditions for PCR 1 were as follows: 1 min at 95ºC, then 25 cycles of 15 sec at 95ºC, 
then 1 min at 58ºC, and 30 sec at 72ºC. Finally, there was 3 minutes at 72ºC and a final 
hold at 4ºC until the sample was removed from the thermocycler. PCR1 products were 
purified with Agencourt Ampure XP beads (Beckman Coulter) with a bead solution to 
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PCR volumetric ratio of 0.6. The samples were washed twice with 70% ethanol and 
eluted in 50 µL of distilled water, final concentrations varied between samples.  
 The components of the second PCR reaction were prepared with a KAPA HiFi 
PCR kit (Kapa Biosystems) using the P1 and indexed primers shown in Table 1, which 
were ordered from Integrated DNA Technologies (Coralville, IA). The cycling 
conditions for PCR2 consisted of 2 min at 95ºC then 35 cycles between 20 sec at 98ºC 
then 15 sec at 63ºC and 30 sec at 72ºC. Finally, there was 3 minutes at 72 ºC and a 
final hold at 4ºC until the sample was removed from the thermocycler. 
Indexed primers. The primers used for each reaction in the second round of PCR were 
Illumina indexed primers, giving each sample a unique, identifiable barcode 
represented by N’s in the primer table. Each sample was numbered (1-24) with each 
number corresponding to that sample’s DNA barcode. 
Purification, quantification and pooling. The quality of the second round PCR 
products was assessed on a test agarose gel and then the DNA products of the 
correct size were gel extracted using the Qiagen MinElute gel extraction kit (Qiagen). 
Each sample was quantified using 1 µL in a Qubit dsDNA Broad Range Assay kit and 
fluorometer (Life Technologies). The concentrations given were then used to create a 
pool of approximately 22 indexed DNA samples in equal concentration with about 200 
ng of each. The combined pool was purified using Agencourt Ampure XP beads 
(Beckman Coulter) with a bead solution to pooled DNA sample volume ratio of 0.6. 
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The combined pool was washed twice with 70% ethanol and eluted from the beads in 
30 µL of distilled water. The final quality of the pooled library was certified using the 
Experion electrophoresis system (Bio-Rad, Hercules, CA), which also revealed the DNA 
strand length. 
Sequencing. The DNA was sequenced using the Primer ID Illumina MiSeq pipeline 
(San Diego, Ca) at the UNC High Throughput Sequencing Facility (HTSF) with analysis 
using 300-nucleotide paired-end sequencing. Each template consensus sequence 
(TCS) was corrected to prevent sequencing errors using a cutoff for the number of raw 
reads. TCS sequences were additionally filtered for large deletions and frameshifts. 
The depth of sequencing was represented by the number of TCSs for each amplicon 
generated from viral RNA extracted from each plasma sample. 
Controls. Each sequencing run included a positive and negative control. The positive 
control was a standard sequencing control library and the negative control was water. 
Each of these expected outcomes of DNA amplification was assessed on the test gel 
before continuing with the sequencing protocol.  
Sequence Analysis using the Poisson Distribution, Error Rate and Confidence 
Intervals. TCSs were first filtered for stop codons and APOBEC3/F hypermutations. 
Then, using a Poisson distribution, a cutoff was generated for assessing minority 
variants and to account for sequencing error. These cutoffs were generated for each 
individual amplicon and sequencing depth based on the number of a particular mutant 
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identified and the number of TCSs for that region. RT region DRMs were based on the 
Stanford HIV-1 drug resistance database (12,13). Each mutation had a calculated 
prevalence and 95% confidence interval; R-software was used for the analysis. 
Web-based application for data analysis. A web-app was used to automatically 
analyze raw MiSeq data from the UNC-HTSF. Sequences were clustered to form 
template consensus sequences (TCSs) and these were further used for identification of 
drug resistance mutation abundance. This web-app provided visual and quantitative 
sequencing data for each sample.  
Statistical analysis. Statistical significance of data was determined using the Mann-
Whitney test to obtain p-values. Hazard ratios (HR) were calculated for different 
measurements to provide the different between two experimental conditions and a 
Fisher’s exact test was used to calculate p values. 
Therapy Failure definition. Therapy failure was defined as not successfully repressed 
on therapy (a viral load >40 copies/mL) by the third time point; participants who were 
successful on therapy became virally suppressed by their third time point without any 
virus rebound.  
Resistance Mutations Identified. The resistance mutations included for analysis in this 
study were identified from the Stanford drug resistance database (12,13) and were 
identified as being impactful in resistance against the drug treatment regimen that all 
the participants were on: TDF/3TC/EFV. The two NRTI mutations of interest were 
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K65R and M184V, and all NNRTI mutations were included, with the most common 
being K103N.  
 
IV. Results 
Participant Demographic Information 
All participants in this study, as aforementioned, were women that were 
pregnant when they entered in to the study. Cohort A had 30 participants with median 
age of 30.5 years (IQR: 26-34) and a median viral load of 4.6 log10 copies/mL (IQR: 
4.1-4.9). Cohort C had 60 participants with a median age of 29 years (IQR: 26-35) and 
a median viral load of 4.2 log10 copies/mL (IQR: 3.8-4.8).  
 
Cohort A Entry Drug Resistance Composition 
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The two cohorts in this study were analyzed separately, women in cohort A 
were treatment naïve and this was their first therapy exposure. Women in cohort C 
had previously discontinued therapy (not due to therapy failure) and were reinitiating 
the same treatment. Figure 1 is a comprehensive summary of participants in cohort A 
based on therapy failure/success and whether or not DRMs were detected in the 
participant's entry sample. The expectation with cohort A was to find drug resistance 
in high abundance in women who were infected with a resistant virus also subsequent 
reversion could lead to a lower abundance at study entry. To understand the effects of 
low level drug resistance mutations on the treatment outcomes, it is important to 
compare the mutations at different abundances using several abundance cut-offs. 
























Figure 1- Cohort A. Presence of drug resistance mutations in success and failure samples from cohort A at 
different sampling sensitivities for HIV-positive study participants. The central percentages indicate the 
sensitivity of DRM detection according to the Poisson distribution. Failure samples were unsuccessful on 
therapy while the success samples became suppressed upon initiation of HIV therapy. Numbers indicate the 
number of participants in each group.
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Primer ID sequencing reveals the true sampling depths of the viral population, which 
allows us to define the detection limit and calculate the confidence intervals of the 
true abundance of minority mutations using the binomial distribution model.  The data 
in Figure 1 (and subsequent figures) were analyzed for all samples where the deep 
sequencing provided sufficient sampling depth of the viral population to detect minor 
variants at 30% abundance, then reanalyzed for the subset of samples where the 
depth of population sequencing allowed for detection of variants at 10% abundance, 
then at 1% abundance. Of note, the total number of individuals dropped with the 
increase in the detection sensitivity because individuals with insufficient TCS numbers 
for that specific cut-off were removed.  
The cohort A participants where entry drug resistance was detected at 30% 
abundance or more in the viral population had a therapy failure rate of 50% (3 out of 
6), while in participants where drug resistance wasn’t detected in the entry sample at 
30% abundance or more 33.3% failed (8 out of 24) giving a hazard ratio of 1.50 
(p=0.641). At higher sensitivities of variant detection the hazard ratio increased to 1.75 
at 10% and 1.80 at 1% sensitivity (p=0.367 and p=0.580). P-values were calculated 
using a Fisher’s exact test. Overall, these data do not indicate a statistically significant 
difference in the rate of therapy failure in women where low level resistance mutations 
were detected versus those where no DRMs were detected. The overall number of 
participants who failed and succeeded the larger population was different from the 
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ratio that we studied as these samples were specifically selected for sequencing in an 
effort to have a 2:1 ratio of therapy success to failure for sequence analysis of minor 
variants (with work ongoing to increase the sample size).  
 
Cohort C Entry Drug Resistance Composition 
 
In total there were 60 entry samples from cohort C analyzed from the 
participants who had previous therapy exposure. DRMs were detected in 26 of the 
cohort C participants (42.6%) with abundance of at least 30%, and in the population 
with DRMs 34.6% experienced therapy failure compared with 23.5% in the participants 




























Figure 1- Cohort C. Presence of drug resistance mutations in success and failure samples from cohort 
C at different sampling sensitivities for HIV-positive study participants. The central percentages indicate 
the sensitivity of DRM detection according to the Poisson distribution. Failure samples were unsuccessful 
on therapy while the success samples became suppressed upon initiation of HIV therapy. Numbers 
indicate the number of participants in each group.
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at a sampling sensitivity of detection of minor variants at 30% abundance (left pie 
chart), as sensitivity increased the hazard ratio fluctuated to 1.38 at 10% and 1.17 at 
1% sensitivity (center and right pie chart, p=0.370 and p= 1.0 respectively). P-values 
were calculated using a Fisher’s exact test. While the difference between these 
populations wasn’t large, there was some indication of separation, although this was 
not statistically significant. Again, the number of participants who failed and 
succeeded is not reflective of the larger population in the cohort as these participants 
were specifically selected for sampling in an effort to have a 2:1 ratio of therapy 
success to failure for analysis (with work ongoing to increase sample size).  
 
Cohort A: DRMs In Therapy Failure Samples 
 
If therapy failure was due to drug resistance, then there is an expectation that 
drug resistance mutations should be highly abundant in the viral population in the 








Figure 2- Cohort A. The proportion of different types of failures at different sensitivity levels. Entry DRMs were present at the 
first time point, new DRMs only arose in a timepoint after the initial timepoint, and failures without DRMs had no drug resistance 
at any time point. The central percentages indicate the sampling sensitivity according to the Poisson distribution and the 
number of TCS sequences for that participant in their entry sample. The number in each pie wedge indicate the number of 
participants that fell in to that category.
30% 10% 1%
Failure w/o DRM detection
Failure w/entry DRMs
Failure w/new DRMs
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sample (when available) for participants who had detectable viral load in spite of 
having initiated therapy (based on the study protocol). The participants who failed on 
therapy were subdivided into three categories: “Failure w/o DRM detection",” Failure 
w/new DRMs,” and “Failure w/entry DRMs” depending on when and if DRMs were 
detected. A priori, there is an expectation that if there are pre-existing drug resistance 
variants (abundant or otherwise) that contribute to therapy failure then they should be 
enriched in the therapy failure sample. A failure to detect any drug resistance 
mutations in the rebound sample would suggest a lack of drug exposure, i.e. a lack of 
adherence.  
The addition of “new-DRMs” incorporates participants who didn’t have 
resistance detected at entry but at later time points had some drug resistance markers 
in the viral population. While these participants were included in the “No Entry DRM 
Detection” for Figure 1, they present an interesting case wherein there may have been 
entry DRMs that were not detected, or intermittent suppression due to poor 
adherence allowed for further replication and the ultimate selection of drug resistance. 
For Cohort A, there were 5 therapy failures that had DRMs at a later time point at 30% 
sensitivity (left pie chart), and of the 3 participants where no DRMs were detected, 
only 1 had a rebound time point that was sequenced, and therefore only 1 is included 
in this figure. In total, 5 out of 6 participants with multiple time points who failed 
without entry DRMs eventually developed drug resistance with high frequency. With 
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samples containing DRMs at two time points, DRM frequency increased or remained 
high if entry abundance was high, as anticipated, for the majority of samples. However 
further sequencing is necessary to confirm these trends. 
  
Cohort C: DRMs In Therapy Failure Samples 
 
Of the 21 cohort C participants who failed therapy 16 had a rebound that could 
be sequenced, of these only two had “new-DRMs” (Figure 2 Cohort C). These 
participants did not have drug resistance at entry, and were therefore categorized as 
“No Entry DRMs'' in Figure 1. Of the 7 samples without DRMs, 5 had the additional 
therapy failure time point that also had no detected drug resistance at 30% sensitivity 
and the other two weren’t included in this figure (left pie chart). This means that at two 
different time points 5 out of 7 (71.4%) participants had no DRM detection, providing 
strong evidence that drug resistance at entry was not a contributor to subsequent 








Figure 2- Cohort C. The proportion of different types of failures at different sensitivity levels. Entry DRMs were 
present at the first time point, new DRMs only arose in a timepoint after the initial timepoint, and failures without 
DRMs had no drug resistance at any time point. The central percentages indicate the sampling sensitivity 
according to the Poisson distribution and the number of TCS sequences for that participant in their entry sample. 
The number in each pie wedge indicate the number of participants that fell in to that category.
30% 10% 1%
Failure w/o DRMs detected
Failure w/entry DRMs
Failure w/new DRMs
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DRMs at two time points, DRM frequency increased or remained high if entry 
abundance was high, as anticipated, for the majority of samples. However further 
sequencing is necessary to confirm these trends. 
  
Entry Viral Load Impact on Therapy Failure 
 
To compare the impact that viral load may have had on treatment failure, the 
women with no entry drug resistance detected were compared to determine whether 
there was a distinguishable difference in the viral load of those who ultimately failed 
therapy compared to those who successfully suppressed the virus. There was not a 
statistically significant difference in cohort A or C, p=0.3503 and p=0.7546 
respectively, according to the Mann-Whitney test. Additionally, in both cohorts the 





















Figure 3. Entry viral loads of participants that succeeded and failed on therapy using 
30% sensitivity samples. Lines represent the median and inner quartile range. Each 
point is a study participant that did not have entry drug resistance mutations detected 
(PA =0.3503, PC =0.7546).
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entry viral load compared with the participants who failed therapy, again emphasizing 
that for these participants the entry viral load was not a significant determinant of 
therapy failure. 
  
Entry DRM Frequency Impact on Therapy Failure in Cohort C  
 
Cohort C was anticipated to have a higher prevalence of drug resistance at 
entry given the previous exposure of cohort C participants to therapy. Therefore, drug 
resistance abundance was considered a more likely predictor of therapy failure in 
cohort C. Figure 4 provides analysis for two different aspects of drug resistance which 
may have predisposed participants to potential therapy failure: multiple DRMs and 
Figure 4. Cohort C Entry Drug Resistance- These figures represent trends in the 10% sensitivity 
populations of study participants in the second exposure participants (cohort C). The left 
figure represents the number of entry drug resistance mutations in the failure and success 
populations (Pleft= 0.047). The right figure models the frequency of the most abundant DRM 
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high entry DRM frequencies. The left panel represents how many different DRMs were 
present (with abundance of at least 10%) in samples from therapy success and failure 
participants at initiation. This graphs show that therapy failure participants tended to 
have more DRMs, specifically 1.625x as many drug resistance mutations, and this 
difference was statistically significant using the Mann-Whitney test (p=0.047). The right 
figure models the entry frequency of the most abundant DRM participants had at 
entry to determine whether the frequency of entry DRMs was impactful in therapy 
outcomes. While therapy failures tended to have larger entry abundance, the number 
of samples was limited and therefore the trend is not statistically significant (p=0.505). 
However, this is promising preliminary data that may provide further interesting 
conclusions following further sequencing. This same analysis will be applied to cohort 






Entry Drug Resistance Composition Without “New-DRMs” 
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To control for the unpredictable nature of participants who had “new-DRMs” 
this figure represents some of the data from Figure 1, while excluding the “new-DRM” 
participants mentioned in Figure 2 or participants who did not have a second time 
point sequenced. For cohort A, 8 participants were excluded reducing those with ‘No 
DRM Detection’ from 24 originally to 16 participants. For cohort C, 3 participants were 
excluded reducing the ‘No DRM Detection’ category from 28 down to the 25 in Figure 
5. Excluding these unclear samples provides an even stronger indication that drug 
resistance was a predictor of therapy failure with a hazard ratio, at the 10% detection 
sensitivity used in this figure, of 6.0 for cohort A and 2.1 for cohort C, for cohort A 


















Cohort A Cohort C
Figure 5. Presence of drug resistance mutations in success and failure samples from cohort C at 10% 
sampling DRM sensitivities for HIV-positive study participants. This figure compares participants with 
entry DRM detection and participants which had no DRM detection at any sequenced time point. The 
number in the center of the circle is total samples and the wedges have numbers of sample represented 
by that outcome.
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a statistically significant outcome and therapy failure was 6 times more likely when 
participants have viruses with drug resistance at entry. While the cohort C outcome is 
not statistically significant, we anticipate further sequencing will solidify this trend. 
 
Fixation of Drug Resistance in Participants with “New-DRMs” 
There is an expectation that drug therapy failure due to drug resistance should 
result in an enrichment of the drug resistance mutations in the sample after therapy 
failure, demonstrating selection due to drug exposure. Poor adherence to therapy as 
the cause of therapy failure would not be expected to select for enrichment of 
resistance-associated mutations in the viral population as the drugs would not be 
consistently present to entirely suppress the non-resistant virus. Of the 5 participants 
in cohort A who had rebound drug resistance, the average DRM frequency in the 
therapy failure sample was 87.7%, and 52.4% for cohort C, although this was from only 
two samples. It is possible the resistance mutations at rebound were present at the 
start of therapy (i.e. entry) but below the level of detection, suggesting "deeper" 
sequencing of these linked entry samples may be warranted. It is also possible that 
there was suboptimal exposure to therapy allowing these mutations to arise 
spontaneously and be selected to high levels within the population.  
 
V. Discussion 
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Ultimately, these preliminary results do not provide a single explanation for why 
drug resistance occurred in these study participants. This data reinforces the complex 
nature of therapy failure, but does support to some degree that drug resistance has 
contributed to therapy failure in participants upon both first and second exposure. The 
distribution of therapy failures presented in Figure 1 for both cohorts A and C 
indicates that the presence of drug resistance alone did present a higher likelihood of 
therapy failure, particularly when excluding the participants with “new-DRMs” as 
presented in Figure 5. However, these trends were only statistically significant for 
Cohort A upon the removal of “new-DRM” participants. Figure 3 clearly presented 
that viral load had no impact of significance on therapy failure in these cohorts, in fact 
indicating that successfully suppressed participants had generally higher entry viral 
loads. However, the number of DRMs was an indicator of therapy failure, as shown in 
Figure 4 for the second exposure participants in cohort C. This data was determined 
to be statistically significant in that, on average, therapy failures had 1.625:1 ratio of 
DRMs as compared to successes with entry DRM detection (p=0.047 according to 
Mann-Whitney test). Cohort C is generally more complex than cohort A, because of 
their previous history of discontinuing therapy. Therefore, it isn’t surprising to consider 
issues of adherence may have arisen for some participants in this cohort. 
The development of drug resistance after therapy initiation is analyzed in Figure 
2 for cohorts A and C. Participants in this category had no DRM detection at entry but 
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detection to some degree in a later time point, usually at high frequencies as 
described above. These new DRM’s present a certain degree of confusion as to their 
source as they were not detected in the entry samples for these participants. One 
potential explanation for our data is that good adherence in the absence of entry 
DRMs shows the chosen drug regimen is highly efficacious; intermittent adherence 
could lead to intermittent suppression which would allow for replication that would 
lead to the evolution of a drug resistant strain; and poor adherence would lead to 
therapy failure without selection for drug resistance. However, another alternative 
explanation for therapy failure with new DRMs is that the entry abundance was too 
low for detection since the level of sensitivity for each sample is determined by how 
"deep" the deep sequencing goes. Further sequencing depth of the entry viral 
population will provide more clarity on the composition of the viral population in these 
samples, however they do indicate the already recognized importance of adherence in 
order to achieve viral suppression.  
In conclusion, entry drug resistance alone has some degree of correlation with 
ultimate therapy failure in participants in cohorts A and C. This preliminary data 
indicates that adherence may be an additional indicator of treatment failure and 
supports the importance of emphasizing adherence as imperative to achieving viral 
suppression and preventing further transmission. Concurrently, the data supports that 
multiple drug resistance mutations additionally increases chances of therapy failure. 
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Viral populations with drug resistance as well as poor adherence has the capability to 
allow for further replication and viral diversification which can lead to selection for 
resistance (if adherence is intermittent) and potentially the spread of multi-drug 
resistant virus strains. This is problematic because multi-resistant strains, which weren’t 
common in this study, have the potential to overcome many multi-drug therapies. 
However, this study indicates that with proper adherence ART targeting only reverse 
transcriptase can successfully suppress viral populations. However, as mentioned in 
early studies, an entry DRM test may be the most effective approach to prevent any 
chance of drug failure, especially in people previously exposed to therapy (5). 
The largest limitation of this study is participant sample numbers. The number 
of samples studied for each cohort is increasing as work continues so this data is only 
preliminary and ultimately nearly 300 participants will be included. An additional 
limitation is the varying viral population sampling depth for characterizing the viral 
populations. While some samples returned hundreds of TCSs (i.e. the number of viral 
genomes sequenced) giving variant detection sensitivity down to 1%, some returned 
10 or less (with 10 needed to detect variant abundance at 30%). The varying numbers 
of TCSs, particularly those with fewer numbers, limit the ability to compare between 
participants and particularly between timepoints of the same participant. Deep 
sequencing is important for the entry samples since that is where the question of the 
role of minor variants in therapy failure is relevant. Deep sequencing of the rebound 
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sample is less important since therapy failure due to drug resistance is expected to 
select for DRMs to a high percentage of the viral population.  
We do not have any reports of adherence from our participants and this data 
could be particularly pertinent to determine a correlation between adherence and 
therapy failure. We have limited certainty that participants in the therapy naïve cohort, 
cohort A, had no previous therapy exposure, and since some participants had high 
entry DRM frequencies we can suppose that some unreported exposure may have 
occurred (or potentially they carried transmitted drug resistance). Finally, all drug 
resistance mutations were treated equally in this study. While analysis was limited only 
to drug resistance mutations relevant to the medications taken by these participants, it 
is likely that some of these mutations may be more impactful in conferring resistance 
than others, and some method of controlling for the comparative impact of mutations 
may be helpful for later analysis.  
As aforementioned, this study provides preliminary data indicating drug 
resistance as a contributor of therapy failure, alongside other factors like adherence. 
Interventions such as entry DRM testing and expanded adherence education have the 
capability to help prevent further treatment failure in this region and beyond. To 
further understand entry drug resistance as it relates to therapy failure, larger numbers 
of participants must be studied as well as acquisition and analysis of later timepoints at 
therapy failure for the participants already analyzed in this paper. This necessary 
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expansion will clarify the results presented here and help to indicate which approaches 
are necessary to prevent treatment failure in this region which has a significant HIV-1 
positive population that is disproportionately targeting a vulnerable part of the 
community – women. 
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